AstraZeneca profit rises 23% to $3.12 billion on cancer drugs, launches $1.5 billion savings plan
Briefing by News4U · First published
Euronews Business reported that AstraZeneca posted a 23% rise in profit after tax to $3.12 billion for the July-September period, driven by oncology sales that reached $7.8 billion, while revenue grew 7% to $16.2 billion. The company launched a "Reshaping for Sustainable Growth" plan to generate $1.5 billion in annual savings, to be reinvested in its pipeline, at a one-off cost of up to $2 billion and largely complete by the end of 2029. It confirmed its 2026 outlook and its target of $80 billion in annual revenue by 2030. [1]
Sources
- AstraZeneca profit jumps 23% on cancer drugs as it unveils major savings plan
Euronews Business · · Full text